PPIDT00109

Drug Information
NameAbatacept
SequenceMHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DrugBank_IDDB01281
Typebiotech
IndicationAbatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and in patients ≥2 years of age for the treatment of active psoriatic arthritis.[L48811] In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.[L20504] Abatacept is also indicated for the prophylaxis of acute graft-versus-host disease, in combination with [methotrexate] and a calcineurin inhibitor such as [tacrolimus], in patients two years of age and older who are undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor.[L20504]

Dosage Forms
Form Route Strength
Solution Other
262.500 mg
Injection, powder, for solution Intravenous
250 MG
Injection, powder, lyophilized, for solution Intravenous
250 mg/15mL
Injection, solution Parenteral; Subcutaneous
125 MG
Injection, solution Parenteral; Subcutaneous
50 MG
Injection, solution Parenteral; Subcutaneous
87.5 MG
Injection, solution Subcutaneous
125 mg/1mL
Injection, solution Subcutaneous
125 mg
Injection, solution Subcutaneous
50 mg/0.4mL
Injection, solution Subcutaneous
50 mg
Injection, solution Subcutaneous
87.5 mg/0.7mL
Injection, solution Subcutaneous
87.5 mg
Powder —
250 mg/1vial
Powder, for solution Intravenous
250 mg / vial
Solution Subcutaneous
125 mg / mL
Injection, powder, lyophilized, for solution Intravenous
26250000 mg
Powder, for solution Intravenous
250 mg
Injection, powder, lyophilized, for solution Intravenous
262.5 MG
Injection Subcutaneous
125 mg
Injection, solution —
125 mg
Solution Subcutaneous
12500000 mg
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P33681 CD80 T-lymphocyte activation antigen CD80 Homo sapiens antagonist Link
target P42081 CD86 T-lymphocyte activation antigen CD86 Homo sapiens antagonist Link
target P16410 CTLA4 Cytotoxic T-lymphocyte protein 4 Homo sapiens inhibitor Link